Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides...
Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Clostridioides difficile
is the leading cause of nosocomial infections and a worldwide urgent public health threat. Without doubt, there is an urgent need for new effective anticlostridial agents due to the increasing incidence and severity of
C. difficile
infection (CDI). The aim of the present study is to investigate the
in vivo
ef...
Alternative Titles
Full title
Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7206065
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7206065
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-020-64882-9
